Benchmark Holdings PLC Notice of Results (5597H)

TIDMBMK

RNS Number : 5597H

Benchmark Holdings PLC

25 November 2022

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

Notice of Q4 and Full Year Results

Webcast for analysts and institutional investors

Equity Development webcast for retail investors

Benchmark Holdings plc (AIM: BMK), the aquaculture biotechnology business, will announce its Q4 and Full Year results, for the three and 12 month periods ended 30 September 2022, on Wednesday 30(th) November 2022.

Webcast for analysts and institutional investors at 9am UK time

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a webcast for analysts and institutional investors on the day at 09:00am UK time. To register your interest, please contact benchmark@mhpgroup.com .

Equity Development webcast for retail investors at 12:00pm UK time

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a separate webcast for retail investors and wealth managers at 12.00pm UK time. The webcast is open to all existing and potential shareholders. Questions can be submitted during the presentation which will be addressed at the end.

To register please visit: https://www.equitydevelopment.co.uk/news-and-events/benchmark-fyresults-presentation-30nov2022

Enquiries

 
 For further information, please contact: 
  Benchmark Holdings plc                     Tel: 0114 240 9939 
  Trond Williksen, CEO 
  Septima Maguire, CFO 
  Ivonne Cantu, Investor Relations 
 
 
  Numis (Broker and NOMAD)                   Tel: 020 7260 1000 
  James Black, Freddie Barnfield, Duncan 
   Monteith 
 
  MHP                                        Tel: 020 3128 8004 
  Katie Hunt, Reg Hoare, Veronica Farah      benchmark@mhpcgroup.com 
 
   Equity Development                         Tel: 020 7065 2692 
   Hannah Crowe

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORDZLFLLFLXFBQ

(END) Dow Jones Newswires

November 25, 2022 02:00 ET (07:00 GMT)

Benchmark (LSE:BMK)
Historical Stock Chart
From Jun 2024 to Jul 2024